SML1227
Tavaborole
≥95% (HPLC), protein synthesis inhibitor, powder
别名:
1,3-Dihydro-5-fluoro-1-hydroxy-2,1-benzoxaborole, 5-Fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborole, AN-2690, AN2690
登录 查看组织和合同定价。
选择规格
变更视图
关于此项目
Assay:
≥95% (HPLC)
Form:
powder
Storage condition:
desiccated
产品名称
Tavaborole, ≥95% (HPLC)
Quality Segment
assay
≥95% (HPLC)
form
powder
storage condition
desiccated
color
white to beige
solubility
DMSO: 20 mg/mL, clear
storage temp.
−20°C
SMILES string
B1(OCc2c1ccc(c2)F)O
InChI
1S/C7H6BFO2/c9-6-1-2-7-5(3-6)4-11-8(7)10/h1-3,10H,4H2
InChI key
LFQDNHWZDQTITF-UHFFFAOYSA-N
General description
Tavaborole is a boron-based pharmaceutical agent. It has broad-spectrum oxaborole antifungal activity. Due to its low molecular weight, it facilitates maximal nail plate penetration than its predecessors.
Biochem/physiol Actions
Tavaborole (AN2690) is a potent antifungal that targets the post-transfer editing site of leucyl-tRNA synthetase (LeuRS).
Tavaborole (AN2690) is a potent antifungal that targets the post-transfer editing site of leucyl-tRNA synthetase (LeuRS). Tavaborole forms a covalent adduct with the 3′ adenosine of tRNA(leu) at the editing site of fungal, but not bacterial LeuRS, locking the enzyme in an inactive conformation. Tavaborole was recently approved for the treatment of onychomycosis of the toenail in adults.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable